|
Steven Heymsfield, M.D.
George A. Bray, Jr. Endowed Super Chair in Nutrition
Executive Director
Department/Laboratory:
Office of Executive Director, PBRC
|
|
Phone:
(225) 763-2513
|
Fax:
(225) 763-0935 |
Send
E-mail
|
EDUCATION
Hunter College, City University of New York, B.A. Chemistry: 1962-1966
Mt. Sinai School of Medicine, New York, NY, M.D. 1969-1971
RESEARCH INTERESTS
Dr. Heymsfield's research focuses primarily on human obesity, including energy regulation, weight loss treatments, and co-morbidity effects. He also has a long term interest in the development of methods for evaluating body composition and the application of new technologies such as fMRI and PET.
SELECTED PUBLICATIONS
1. Heymsfield SB, Cefalu WT. Does body mass index adequately convey a patient’s mortality risk? JAMA. 2013;309:87-8. PMID: 23280230.
2. Katzmarzyk PT, Heymsfield SB, Bouchard C. Clinical utility of visceral adipose tissue for the identification of cardiometabolic risk in white and African American adults. Am J Clin Nutr. 2013;97(3):480-6. PMID: 23364010.
3. Casazza K, Fonataine KR, Astrup A, Birch LL, Brown AW, Bohan Brown MM, Durant N, Dutton G, Foster EM, Heymsfield SB, McIver K, Mehta T, Menachemi N, Newby PK, Pate R, Rolls BJ, Sen B, Smith DL Jr, Thomas DM, Allison DB. Myths, presumptions, and facts about obesity. N Engl J Med. 2013;368(5):446-54. PMID:23363498.
4. Metzger AL, Adler R, Heymsfield SB, Grundy SM. Diurnal variation in biliary lipid composition. N Eng J Med 288:333-336, 1973.
5. Heymsfield SB, Bethel RA, Hall EC, Mills JB, Moseley MH, Kostyo JL, Rudman D. Anabolic actions of reduced and S-Carbamidomethylated human growth hormone and its plasmin digest in man. J Clin Invest 60:563-570, 1977.
6. Heymsfield SB, Bethel RA, Ansley JD, Nixon DW, Rudman D: Enteral hyperalimentation: an alternative to central venous hyperalimentation. Ann Intern Med 90:63-71, 1979.
7. Smith JL, Arteaga C, Heymsfield SB. Increased ureagenesis and impaired nitrogen use during infusion of a synthetic amino acid formula. N Eng J Med 306:1013-1018, 1982.
8. Heymsfield SB, Smith- Andrews JL, Hersh T. Home nasoenteric feeding for malabsorption and weight loss refractory to conventional therapy. Ann Intern Med. 98:168-170, 1983.
9. Lichtman SW, Pisarska K, Berman E, Pestone M, Dowling H, Offenbacher E, Weisel H, Heshka S, Matthews DE, Heymsfield SB. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Eng J Med 327:1893-1898, 1992.
10. Rosenbaum M, Ravussin E, Matthews DE, Gilker C, Ferraro R, Heymsfield SB, Hirsch J, Leibel RL. A comparative study of different means of assessing long-term energy expenditure in humans. Am J Physiol 270:496-504, 1996.
11. Pietrobelli A, Formica C, Wang ZM, Heymsfield SB. Dual-energy X-ray absorptiometry body composition model: review of physical concepts. Am J Physiol 271:941-51, 1996
12. Gallagher D, Belmonte D, Deurenberg P, Wang ZM, Krasnow N, Pi-Sunyer FX, Heymsfield SB. Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass. Am J Physiol 275(2): E249-E258, 1998.
13. Heymsfield SB, Allison DB, Vasselli JR, Greenfield D, Nuñez C. Garcinia cambogia (Hydroxycitric Acid) as a potential anti-obesity agent: A randomized-double blind controlled trial. JAMA 280 (18): 1596-1600, 1998.
14. Davidson M, DiGirolamo M, Foreyt J, Halstead C, Hauptman J, Heber D, Heimburger D, Heymsfield SB, Lucas C, Robbins D, Chung J. Long-term weight control and reduction in risk factors in obese subjects receiving orlistat: a lipase inhibitor. JAMA 281 (3): 875-883, 1999.
15. Heymsfield SB, Greenberg AS, Fujioka K, Dixon R, Kushner R, Hunt T, Patane J, Self B, McCamish M, Hunt P, Lubina J. Preliminary Safety and Efficacy of Leptin in Lean and Obese Subjects. JAMA 282:1230-1240, 1999
16. Wang ZM, Deurenberg P, Wang W, Pietrobelli A, Baumgartner RN, Heymsfield SB. Hydration of fat-free body mass: new physiological modeling approach. Am J Physiol 276: E995-E1003, 1999.
17. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JPH, Sjostrom L. Weight loss with orlistat improves glucose tolerance and reduces progression to impaired glucose tolerance and type 2 diabetes in obese adults. Arch Int Med.160: 1321-1326, 2000.
18. Gallagher D, Ruts E, Visser M, Heshka S, Baumgartner RN, Wang J, Pierson RN, Pi-Sunyer FX, Heymsfield SB. Weight stability masks sarcopenia in elderly men and women. Am J Physiol 279: E366-E375, 2000.
19. Wang ZM, Heshka S, Gallagher D, boozer C, Kotler D, Heymsfield SB. Resting energy expenditure fat-free mass relationship: new insights provided by body composition modeling. Am J Physiol. 279: E539-E545, 2000.
20. Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, Leibel RL. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab 87:2391-2394, 2002.
21. Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Heyman ER, Stambler N, Vicary C, Guler HP. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: A randomized, dose-ranging study. JAMA 2003;289(14): 1826-1832.
22. Hayes M, Chustek M, Heshka S, Wang Z, Pietrobelli A, Heymsfield SB. Low physical activity levels of modern Homo sapiens among free-ranging mammals. Int J Obes. 2005;29:151-6.
23. Rosenbaum M, Goldsmith R, Bloomfield D, Magnano A, Weimer L, Heymafield SB, Gallagher D, Mayer L, Murphy E, Leibel RL. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. The Journal of Clinical Investigation 2005; 115(12):3579-86.
24. Erondu N, Addy C, Lu K, Mallick M, Musser B, Gantz I, Proietto J, Astrup A, Toubro S, Rissannen AM, Tonstad S, Haynes WG, Gottesdiener KM, Kaufman KD, Amatruda JM, Heymsfield SB. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. Obesity 2007;15:2027-42
25. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohórquez SM, Stoch A, Stevens C, Fong TM, De Lepeleire I, Cilissen C, Cote J, Rosko K, Gendrano IN 3rd, Nguyen AM, Gumbiner B, Rothenberg P, de Hoon J, Bormans G, Depré M, Eng WS, Ravussin E, Klein S, Blundell J, Herman GA, Burns HD, Hargreaves RJ, Wagner J, Gottesdiener K, Amatruda JM, Heymsfield SB. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 2008;7:68-78
26. Heymsfield SB, Thomas D, Nguyen AM, Peng JZ, Martin C, Shen W, Strauss B, Bosy-Westphal A, Muller MJ. Voluntary weight loss: systematic review of early phase body composition changes. Obes Rev. 2011; 12:e348-61.
27. Thomas D, Das SK, Levine JA, Martin CK, Mayer L, McDougall A, Strauss BJ, Heymsfield SB. New fat free mass - fat mass model for use in physiological energy balance equations. Nutr Metab (Lond). 2010; 7:39.
28. Thomas DM, Schoeller DA, Redman LA, Martin CK, Levine JA, Heymsfield SB. A computational model to determine energy intake during weight loss. Am J Clin Nutr. 2010; 92:1326-31.
29. Thomas DM, Navarro-Barrientos JE, Rivera DE, Heymsfield SB, Bredlau C, Redman LM, Martin CK, Lederman SA, M Collins L, Butte NF. Dynamic energy-based model predicting gestational weight gain. Am J Clin Nutr. 2012;95:115-22.
30. Myers MG Jr., Heymsfield SB, Haft C, Kahn BB, Laughlin M, Leibel RL, Tschop MH, Yanovski JA. Challenges and opportunities of defining clinical leptin resistance. Cell Metab. 2012;15:150-6.
31. Hall KD, Heymsfield SB, Kemnitz JW, Klein S, Schoeller DA, Speakman JR. Energy blanace and its components: implications for body weight regulation. Am J Clin Nutr. 2012;95:989-94.
^ top
More Sites
